What Is DSIP?

Research Overview

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first isolated in 1974 by the Schoenenberger-Monnier group at the University of Basel, Switzerland, from the cerebral venous blood of rabbits in electrically induced slow-wave sleep. DSIP-like immunoreactivity has since been detected in the hypothalamus, limbic system, pituitary gland, and human breast milk.[1][17]

DSIP remains neuroscience's "unresolved riddle": despite 50+ years of study, no specific gene coding for a DSIP precursor has been identified, and no dedicated receptor has been cloned. Sequence analysis suggests homology with the 324–332 fragment of human lysine-specific histone demethylase 3B (KND peptide, JMJD1B gene).[1]

Originally pursued as a "somnogenic molecule" to cure insomnia, the therapeutic rationale shifted to that of a "programming modulator" or adaptogen — stabilizing neuronal activity and restoring homeostasis under stress or disrupted circadian rhythms. Research spans 8+ indication categories across neurology, addiction medicine, oncology, cardiology, and gerontology.[9]

Discovery and historical context: The Schoenenberger-Monnier program at Basel pursued the "humoral hypothesis of sleep" — that a circulating factor accumulating during wakefulness drives the transition into slow-wave sleep. Cerebral venous blood from rabbits in electrically-induced thalamic-stimulated sleep was dialyzed and infused into recipient rabbits, reproducing the delta-EEG signature. The active fraction was isolated, sequenced as a linear nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, MW 848.81 Da), and synthesized — the synthetic preparation reproduced the EEG-modifying activity of the natural extract.[1][17]

Research framework: DSIP exhibits an unusual pharmacological profile that distinguishes it from receptor-targeted neuropeptides — bell-shaped dose-response, partial blood-brain-barrier penetration, ~15-min plasma half-life with rapid N-terminal tryptophan cleavage by aminopeptidases, and no cloned receptor. The aminopeptidase-resistant analog [D-Ala²]DSIP and the more-potent KND peptide (WKGGNASGE, single Asp→Asn substitution at position 5) are the standard structural tools used in modern preclinical studies to dissect the underlying signaling. Investigators studying related stress-modulating and neuroprotective peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel adaptogen pharmacology and circadian-rhythm modulation in rodent models.[9]